ASCVD Risk Score: Calculation and Treatment Guidance
Calculate the patient's 10-year ASCVD risk using the ACC/AHA Pooled Cohort Equations for adults aged 40-75 years, which estimates the risk of first hard atherosclerotic cardiovascular disease events (coronary heart disease death, nonfatal MI, or stroke) and directly guides statin therapy decisions. 1
How to Calculate the Risk Score
The Pooled Cohort Equations provide sex- and race-specific estimates for non-Hispanic African Americans and non-Hispanic Whites aged 40-79 years 1. For other ethnic groups, use the equations for non-Hispanic Whites 1.
Required variables:
- Age
- Total cholesterol
- HDL cholesterol
- Systolic blood pressure (and whether treated)
- Diabetes status (yes/no)
- Current smoking status (yes/no)
Access the calculator at: http://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/ 2
Risk Categories and Treatment Thresholds
The calculated 10-year risk stratifies patients into actionable categories:
Treatment Recommendations Based on Risk Score
High-Intensity Statin (≥50% LDL-C reduction)
Initiate immediately for:
- Primary LDL-C ≥190 mg/dL (regardless of risk score) 4
- Diabetes + 10-year ASCVD risk ≥7.5% 4, 5
- 10-year ASCVD risk ≥20% 3
Moderate-to-High Intensity Statin
Strongly recommended for:
- 10-year ASCVD risk ≥7.5% to <20% (intermediate risk) 4, 5
- All adults 40-75 years with diabetes, regardless of calculated risk 4, 5
Moderate-Intensity Statin
Reasonable to offer for:
- 10-year ASCVD risk 5% to <7.5% (borderline risk) 4
Consider Withholding or Deferring Statins
For borderline or intermediate risk when:
- Patient preferences favor deferral after risk discussion 4
- Coronary artery calcium score = 0 (especially if non-smoker, no family history of premature CAD) 2
Refining Risk Assessment with Coronary Artery Calcium Scoring
When the treatment decision is uncertain (particularly in borderline or intermediate risk), coronary artery calcium scoring (CACS) provides objective atherosclerosis burden assessment 2:
CACS = 0
- Borderline risk: Actual 10-year risk drops to 1.5% → statins not recommended 2
- Intermediate risk: Actual 10-year risk 1.5-3.0% → consider deferring statins 2
- Reassess in 3-5 years if risk factors present 2
CACS 1-99
- Borderline risk: Actual 10-year risk increases to 7.4% → statins recommended 2
- Intermediate risk: Favor statin treatment, especially age >55 years 2
CACS ≥100 or ≥75th percentile for age/sex/race
- Statin therapy strongly recommended regardless of initial risk category 2
- Event rate approximates secondary prevention population (≥20 events per 1000 person-years) 2
Risk-Enhancing Factors
When borderline or intermediate risk and decision remains uncertain, presence of these factors favors statin initiation 5:
- Family history of premature ASCVD
- Persistently elevated LDL-C ≥160 mg/dL
- Metabolic syndrome
- Chronic kidney disease
- History of preeclampsia or premature menopause
- Chronic inflammatory disorders (rheumatoid arthritis, psoriasis, HIV)
- High-risk ethnicity (South Asian)
- Persistently elevated triglycerides ≥175 mg/dL
- High-sensitivity CRP ≥2.0 mg/L
- Ankle-brachial index <0.9
- Lipoprotein(a) >50 mg/dL
Important Caveats
The 2023 PREVENT equations represent an update that removes race, adds kidney function and statin use variables, and generally produces lower risk estimates than the Pooled Cohort Equations 6. Using PREVENT instead of PCE could reduce statin-eligible adults from 45.4 million to 28.3 million in the U.S. 6. However, current ACC/AHA guidelines still reference the Pooled Cohort Equations 1, 4, 5, making them the standard for clinical decision-making until guidelines formally adopt PREVENT.
Always engage in clinician-patient risk discussion before initiating statin therapy, addressing potential benefits, adverse effects, drug interactions, lifestyle modifications, and patient preferences 4, 5.
Lifestyle modification remains foundational regardless of risk score or statin decision 2.